The U.S. Supreme Court left intact a patent ruling that may cost a Medtronic Inc. (MDT:US) unit more than $200 million in its clash with Edwards Lifesciences Corp. (EW:US) over devices that repair aortic valves without open-heart surgery. The justices today turned away an appeal from Medtronic’s CoreValve unit, which a jury concluded infringed an Edwards heart-valve patent. A lower court upheld the jury’s $74 million verdict in November.
Help employers find you! Check out all the jobs and post your resume.
